Reckitt Benckiser (Bangladesh) PLC (DSE:RECKITTBEN)
3,397.70
+9.10 (0.27%)
At close: Aug 7, 2025
Inozyme Pharma Balance Sheet
Financials in millions BDT. Fiscal year is January - December.
Millions BDT. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Cash & Equivalents | 944.37 | 2,203 | 2,919 | 1,978 | 1,629 | 1,789 | Upgrade |
Cash & Short-Term Investments | 944.37 | 2,203 | 2,919 | 1,978 | 1,629 | 1,789 | Upgrade |
Cash Growth | -66.54% | -24.56% | 47.58% | 21.43% | -8.94% | 33.38% | Upgrade |
Accounts Receivable | 139.65 | 121.65 | 129.23 | 57.67 | 67.71 | 22.96 | Upgrade |
Other Receivables | - | 6.69 | 6.32 | 2.53 | 1.3 | 2.54 | Upgrade |
Receivables | 139.65 | 128.35 | 135.56 | 60.21 | 69.01 | 25.5 | Upgrade |
Inventory | 641.71 | 707.51 | 581.31 | 580.08 | 584.82 | 621.62 | Upgrade |
Prepaid Expenses | - | - | - | 13.99 | 30.71 | 39.05 | Upgrade |
Other Current Assets | 34.9 | 26.49 | 53.63 | 17.63 | 14.94 | 36.94 | Upgrade |
Total Current Assets | 1,761 | 3,065 | 3,690 | 2,650 | 2,329 | 2,512 | Upgrade |
Property, Plant & Equipment | 772.12 | 711.78 | 750.07 | 745.76 | 726.61 | 725.22 | Upgrade |
Long-Term Deferred Tax Assets | 42.66 | 53.01 | 26.76 | - | 10.89 | 28.76 | Upgrade |
Other Long-Term Assets | 25.43 | 28.81 | 25.33 | - | - | - | Upgrade |
Total Assets | 2,601 | 3,859 | 4,492 | 3,396 | 3,066 | 3,266 | Upgrade |
Accounts Payable | 1,869 | 353.51 | 307.56 | 397.65 | 232.35 | 159.3 | Upgrade |
Accrued Expenses | 3.87 | 353.25 | 1,130 | 901.98 | 1,336 | 1,562 | Upgrade |
Short-Term Debt | - | 69.33 | 30.99 | - | - | - | Upgrade |
Current Portion of Leases | 28.59 | 21.22 | 37.7 | 36.94 | 10.09 | 18.21 | Upgrade |
Current Income Taxes Payable | 115.44 | 174.24 | 176.84 | 143.75 | 187.21 | 219.57 | Upgrade |
Other Current Liabilities | 5.63 | 1,021 | 1,438 | 896.76 | 128.64 | 179.01 | Upgrade |
Total Current Liabilities | 2,023 | 1,992 | 3,121 | 2,377 | 1,894 | 2,138 | Upgrade |
Long-Term Leases | 164.95 | 109.14 | 132.65 | 150.41 | 153.55 | 149.32 | Upgrade |
Long-Term Deferred Tax Liabilities | - | - | - | 1.7 | - | - | Upgrade |
Total Liabilities | 2,224 | 2,202 | 3,298 | 2,561 | 2,118 | 2,458 | Upgrade |
Common Stock | 47.25 | 47.25 | 47.25 | 47.25 | 47.25 | 47.25 | Upgrade |
Retained Earnings | 329.82 | 1,610 | 1,147 | 788.14 | 900.81 | 760.47 | Upgrade |
Shareholders' Equity | 377.07 | 1,657 | 1,194 | 835.39 | 948.06 | 807.72 | Upgrade |
Total Liabilities & Equity | 2,601 | 3,859 | 4,492 | 3,396 | 3,066 | 3,266 | Upgrade |
Total Debt | 193.55 | 199.69 | 201.33 | 187.35 | 163.64 | 167.54 | Upgrade |
Net Cash (Debt) | 750.83 | 2,003 | 2,718 | 1,791 | 1,465 | 1,622 | Upgrade |
Net Cash Growth | -69.06% | -26.31% | 51.78% | 22.21% | -9.63% | 23.56% | Upgrade |
Net Cash Per Share | 158.91 | 423.89 | 575.27 | 379.02 | 310.14 | 343.18 | Upgrade |
Filing Date Shares Outstanding | 4.73 | 4.73 | 4.73 | 4.73 | 4.73 | 4.73 | Upgrade |
Total Common Shares Outstanding | 4.73 | 4.73 | 4.73 | 4.73 | 4.73 | 4.73 | Upgrade |
Working Capital | -262.21 | 1,073 | 568.79 | 273.07 | 434.53 | 374.41 | Upgrade |
Book Value Per Share | 79.80 | 350.64 | 252.69 | 176.80 | 200.65 | 170.95 | Upgrade |
Tangible Book Value | 377.07 | 1,657 | 1,194 | 835.39 | 948.06 | 807.72 | Upgrade |
Tangible Book Value Per Share | 79.80 | 350.64 | 252.69 | 176.80 | 200.65 | 170.95 | Upgrade |
Land | - | 0.21 | 0.21 | 0.21 | 0.21 | 0.21 | Upgrade |
Buildings | - | 305.26 | 295.72 | 304.35 | 286.41 | 269.5 | Upgrade |
Machinery | - | 947.54 | 866.73 | 840.42 | 735.61 | 647.27 | Upgrade |
Construction In Progress | - | 190.09 | 171.23 | 74.98 | 96.54 | 79.1 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.